FDA Wants More "Predictable" Revenue Stream Under PDUFA III
This article was originally published in The Tan Sheet
Executive Summary
FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.
You may also be interested in...
User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal
The design of FDA's user fee system should encourage attention to the entire life cycle of a product, Center for Devices & Radiologic Health Director David Feigal, MD, said at the Food & Drug Law Institute meeting in Washington, D.C. June 5.
User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal
The design of FDA's user fee system should encourage attention to the entire life cycle of a product, Center for Devices & Radiologic Health Director David Feigal, MD, said at the Food & Drug Law Institute meeting in Washington, D.C. June 5.
User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal
The design of FDA's user fee system should encourage attention to the entire life cycle of a product, Center for Devices & Radiologic Health Director David Feigal, MD, said at the Food & Drug Law Institute meeting in Washington, D.C. June 5.